AKT3 and colorectal carcinoma: reported that the activation of AKT3 and AKT1 in drug‐resistant CRC cells leads to the dysregulation of miR‐125b‐5p and the overexpression of GLUT5, which in turn increases the migration and invasion of CRC cells and bolsters their resistance to oxaliplatin and 5‐FU [47].